US 11,788,068 B2
Modified/mutant bacterial luciferases
Shawn Lee Suko, Walnut Creek, CA (US)
Assigned to Roche Molecular Systems, Inc., Pleasanton, CA (US)
Appl. No. 16/758,372
Filed by Roche Molecular Systems, Inc., Pleasanton, CA (US)
PCT Filed Oct. 25, 2018, PCT No. PCT/EP2018/079234
§ 371(c)(1), (2) Date Apr. 22, 2020,
PCT Pub. No. WO2019/081620, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/576,814, filed on Oct. 25, 2017.
Prior Publication US 2020/0339964 A1, Oct. 29, 2020
Int. Cl. C12N 9/02 (2006.01)
CPC C12N 9/0069 (2013.01) [C12N 9/0071 (2013.01); C12Y 114/14003 (2013.01)] 5 Claims
 
1. A modified bacterial luciferase having improved activity as compared to a control bacterial luciferase, wherein the improved activity is an increase in light production and/or slower signal decay, wherein the LuxA subunit of the modified bacterial luciferase comprises an amino acid sequence that is at least 99% identical to the LuxA subunit of the control bacterial luciferase, wherein the LuxA subunit of the control bacterial luciferase has the amino acid sequence of SEQ ID NO:2, wherein:
(a) the amino acid of the modified bacterial luciferase corresponding to position 170 of SEQ ID NO:2 is R, W, or K;
(b) the amino acid of the modified bacterial luciferase corresponding to position 102 of SEQ ID NO:2 is K;
(c) the amino acid of the modified bacterial luciferase corresponding to position 22 of SEQ ID NO:2 is H; or
(d) the amino acid of the modified bacterial luciferase corresponding to position 166 of SEQ ID NO:2 is Y.